Bad Homburg (ots) - Global healthcare company Fresenius Kabi will announce the winner of the first EUR 100,000* Parenteral Nutrition Research Grant Latin America at the FELANPE congress in Guadalajara, Mexico, from September 22-25.
The announcement will be made during Fresenius Kabi's satellite symposium, in Salón 7, on September 24, from 10.45am - 12.45pm (CDT).
The EUR 100,000* winner will be a healthcare professional with an original research project directly related to the therapeutic area of parenteral nutrition. The funding is for a research project lasting two years, starting in October 2018. Results of the project are expected to be presented at the FELANPE congress in 2020.
Fifty-one applications from nine countries across Latin America were received for the first ever Parenteral Nutrition Research Grant Latin America. The majority of applicants came from Brazil and Mexico. The winner has been chosen by an independent Research Grant Committee, consisting of renowned key opinion leaders in the field of clinical nutrition in Latin America and was chaired by Prof. Isabel Correia, the former FELANPE president.
With this research grant, Fresenius Kabi aims to encourage and support clinical research, advancing the use of parenteral nutrition across Latin America, within the scope of its initiative 'United for clinical nutrition'. Once developed, these insights contribute to improving patient outcomes across the region.
*Euro amount or equivalent in local currency
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
Originaltext: Fresenius Kabi digital press kits: http://www.presseportal.de/nr/106045 press kits via RSS: http://www.presseportal.de/rss/pm_106045.rss2
Media Relations Contact: Isabel Cochrane +49 (0)69/401254353 Isabel.Cochrane@edelman.com
The announcement will be made during Fresenius Kabi's satellite symposium, in Salón 7, on September 24, from 10.45am - 12.45pm (CDT).
The EUR 100,000* winner will be a healthcare professional with an original research project directly related to the therapeutic area of parenteral nutrition. The funding is for a research project lasting two years, starting in October 2018. Results of the project are expected to be presented at the FELANPE congress in 2020.
Fifty-one applications from nine countries across Latin America were received for the first ever Parenteral Nutrition Research Grant Latin America. The majority of applicants came from Brazil and Mexico. The winner has been chosen by an independent Research Grant Committee, consisting of renowned key opinion leaders in the field of clinical nutrition in Latin America and was chaired by Prof. Isabel Correia, the former FELANPE president.
With this research grant, Fresenius Kabi aims to encourage and support clinical research, advancing the use of parenteral nutrition across Latin America, within the scope of its initiative 'United for clinical nutrition'. Once developed, these insights contribute to improving patient outcomes across the region.
*Euro amount or equivalent in local currency
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
Originaltext: Fresenius Kabi digital press kits: http://www.presseportal.de/nr/106045 press kits via RSS: http://www.presseportal.de/rss/pm_106045.rss2
Media Relations Contact: Isabel Cochrane +49 (0)69/401254353 Isabel.Cochrane@edelman.com